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Abstract
Aims/hypothesis Mucosal-associated invariant T (MAIT) cells are innate-like T cells that recognise derivatives of bacterial
riboflavin metabolites presented by MHC-Ib-related protein 1 (MR1) molecules and are important effector cells for mucosal
immunity. Their development can be influenced by the intestinal microbiome. Since the development of type 1 diabetes has been
associated with changes in the gut microbiome, this can be hypothesised to lead to alterations in circulating MAIT cells.
Accordingly, peripheral blood MAIT cell alterations have been reported previously in patients with type 1 diabetes. However,
a comprehensive analysis of the frequency and phenotype of circulating MAIT cells at different stages of type 1 diabetes
progression is currently lacking.
Methods We analysed the frequency, phenotype and functionality of peripheral blood MAIT cells, as well as γδ T cells, invariant
natural killer T (iNKT) cells and natural killer (NK) cells with flow cytometry in a cross-sectional paediatric cohort (aged 2–15)
consisting of 51 children with newly diagnosed type 1 diabetes, 27 autoantibody-positive (AAb+) at-risk children, and 113 healthy
control children of similar age and HLA class II background. The frequency of MAIT cells was also assessed in a separate cross-
sectional adult cohort (aged 19–39) of 33 adults with established type 1 diabetes and 37 healthy individuals of similar age.
Results Children with newly diagnosed type 1 diabetes displayed a proportional increase of CD8−CD27− MAIT cells compared
with healthy control children (median 4.6% vs 3.1% of MAIT cells, respectively, p = 0.004), which was associated with reduced
expression of C-C chemokine receptor (CCR)5 (median 90.0% vs 94.3% of MAIT cells, p = 0.02) and β7 integrin (median
73.5% vs 81.7% of MAIT cells, p = 0.004), as well as decreased production of IFN-γ (median 57.1% vs 69.3% of MAIT cells,
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p = 0.04) by the MAIT cells. The frequency of MAIT cells was also decreased in AAb+ children who later progressed to type 1
diabetes compared with healthy control children (median 0.44% vs 0.96% of CD3+ T cells, p = 0.04), as well as in adult patients
with a short duration of type 1 diabetes (less than 6 years after diagnosis) compared with control individuals (median 0.87% vs
2.19% of CD3+ T cells, p = 0.007). No alterations in γδ T cell, iNKT cell or NK cell frequencies were observed in children with
type 1 diabetes or in AAb+ children, with the exception of an increased frequency of IL-17A+ γδ T cells in children with newly
diagnosed diabetes compared with healthy control children (median 1.58% vs 1.09% of γδ T cells, p = 0.002).
Conclusions/interpretation Changes in the frequency and phenotype of circulating MAIT cells were detectable before, at the
onset and after diagnosis of type 1 diabetes in cross-sectional cohorts. Our results suggest a possible temporal association
between peripheral blood MAIT cell alterations and the clinical onset of type 1 diabetes.
Keywords Autoimmunity . Human . Immunophenotyping .MAIT cells . Mucosal immunity . T cells . Type 1 diabetes
Abbreviations
AAb+ Autoantibody-positive
CCR C-C chemokine receptor
DN Double negative
DP Double positive
IBD Inflammatory bowel disease
iNKT Invariant natural killer T (cell)
MAIT Mucosal-associated invariant T (cell)
MR1 MHC-Ib-related protein 1
NK Natural killer
PBMC Peripheral blood mononuclear cell
PD-1 Programmed cell death protein 1
PMA Phorbol myristic acid
SLE Systemic lupus erythematosus
TCR T cell receptor
UCT cell Unconventional T cell
Introduction
Type 1 diabetes is a chronic autoimmune disease caused by
progressive T cell-mediated destruction of insulin-producing
beta cells in the pancreas [1]. The clinical presentation of type
1 diabetes is preceded by a period of asymptomatic autoim-
munity, during which autoantibodies to islet antigens are
almost invariably detected [2, 3].
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The incidence of type 1 diabetes has increased considerably in
the past 30 years [4, 5]. Despite over 50 susceptibility loci shown
to contribute to the development of type 1 diabetes in humans [6,
7], the autoimmune process in genetically at-risk individuals is
probably driven by environmental factors, such as infections and
diet [8]. Importantly, the composition of the intestinalmicrobiome
has recently been associated with the development of type 1
diabetes. Compared with healthy control individuals of similar
age, both patients with type 1 diabetes [9–12] and autoantibody-
positive (AAb+) children at risk for type 1 diabetes [13–16] have
been reported to display decreased bacterial diversity as well as
intestinal dysbiosis commonly characterised by increased
numbers of Bacteroidetes species in the gut microbiome.
The intestinal microbiome also plays a key role in the devel-
opment of certain subsets of innate-like T cells, such as the
mucosal-associated invariant T (MAIT) cells. MAIT cells are
preferentially localised in mucosal tissues, including gut, and are
largely absent in germ-free mice [17, 18]. Together with γδ T
cells and invariant natural killer T (iNKT) cells, MAIT cells are
classified as unconventional T cells (UCTs) [19]. MAIT cells
express a conserved T cell receptor (TCR) comprising an invari-
ant Vα7.2-Jα33 chain, and they recognisemetabolites originating
frommicrobial biosynthesis presented byMHC-Ib-related protein
1 (MR1) on antigen-presenting cells [19]. Upon activation,MAIT
cells produce several proinflammatory cytokines, such as IFN-γ
and IL-17A, and display cytotoxic effector function against cells
infected with certain pathogens [20]. Similar to conventional T
cells, MAIT cells develop in the thymus before migrating into the
peripheral blood and accumulate in circulation with age [18, 21,
22]. Human peripheral blood MAIT cells express high levels of
CD1 6 1 a n d I L - 1 8 r e c e p t o r α , w h i c h t o g e -
ther with TCR Vα7.2 can be used in their identification [21].
In recent years, alterations in the circulating MAIT
compartment have been observed in multiple autoimmune
diseases, such as inflammatory bowel disease (IBD)
[23–26], systemic lupus erythematosus (SLE) [27, 28], rheu-
matoid arthritis [27, 29, 30] and multiple sclerosis [31–33].
The first published study on MAIT cells in patients with type
1 diabetes reported a comparable frequency of circulating
CD8+CD161bright ‘MAIT-like’ cells in individuals with type
1 diabetes compared with healthy control individuals [34]. A
more recent study observed a markedly reduced frequency of
circulating MAIT cells in patients with newly diagnosed type
1 diabetes [35]. One more study suggested that the frequency
of circulating MAIT cells was also reduced in AAb+ at-risk
individuals [36]. Variable alterations in CD25, programmed
cell death protein 1 (PD-1), C-C chemokine receptor type
(CCR)6 and CD27 surface marker expression, as well as
IFN-γ and IL-4 production, by peripheral blood MAIT cells
from individuals with type 1 diabetes have also been reported
in these studies [34, 35].
In order to better understand the role of MAIT cells during
type 1 diabetes development, we analysed blood MAIT cell
frequency, phenotype and function in samples from individ-
uals at different stages of diabetes progression.
Methods
Study participants The paediatric study cohort comprised a
total of 51 children with newly diagnosed type 1 diabetes,
27 AAb+ children, and 113 autoantibody-negative healthy
children (Table 1). Among the AAb+ children, 11 were diag-
nosed with type 1 diabetes 3–33 months (mean ± SD 13.7 ±
10.5 months) after sampling (progressors) and 16 had not
progressed to clinical disease (non-progressors) during the
mean 3 year follow-up after sampling. Except for children
with newly diagnosed type 1 diabetes, all study participants,
including the autoantibody-negative healthy control children,
participated in the Finnish Type 1 Diabetes Prediction and
Prevention (DIPP) follow-up study and had HLA genotypes
associated with increased risk for type 1 diabetes [37].
Autoantibody-positivity was analysed in the children at
sampling, as previously described [2]. AAb+ children were
positive for two or more biochemical autoantibodies (insulin
autoantibodies [IAA], insulinoma-associated-2 antibodies
[IA-2A], GAD antibodies [GADA] and/or zinc transporter 8
autoantibodies [ZnT8A]).
The adult study cohort comprised 33 adults with
established type 1 diabetes and 37 healthy individuals
(Table 1).
The study was approved by local ethics committees in the
participating university hospitals. All individuals participating
in the study and/or their legal guardians provided written
informed consent, as mandated by the Declaration of Helsinki.
PBMC sample preparation Peripheral bloodmononuclear cells
(PBMCs) were isolated from peripheral blood samples as
previously described [38]. Fresh PBMCs from paediatric
participants and frozen PBMCs (cryopreserved in 10%
DMSO) from adult participants were used for cell culture
and immunostaining experiments.
Cell culture and stimulation PBMCs were seeded in U-bottom
96-well plates (106 per 200 μl per well) and cultured for 16–
18 h (37°C, 5% CO2) in RPMI 1640 complete medium with
5% human AB serum. Cells were either left unstimulated or
stimulated with whole Escherichia coli bacteria (ATCC strain
25922, Manassas, VA, USA) fixed with 1% paraformalde-
hyde for 5 min [39], or with a combination of IL-12 and IL-
18 (both at 50 ng/ml, Peprotech, Cranbury, NJ, USA). Some
samples were preincubated either with anti-MR1 blocking
antibody (20 μg/ml, clone 26.5, BioLegend, San Diego, CA,
USA) or with IgG2a isotype control (20 μg/ml, clone MPOC-
173, BioLegend) prior to E.coli stimulation.
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Flow-cytometric analyses Viability staining was performed
on PBMCs using Zombie Aqua dye (BioLegend) accord-
ing to the manufacturer’s instructions. Immunostaining
for surface markers was subsequently performed on at
least 106 PBMCs per staining by incubating the cells with
a panel of fluorochrome-labelled antibodies (ESM
Table 1) for 20–30 min. For cytokine analyses PBMCs
were stimulated for 5 h with 20 ng/ml phorbol myristic
acid (PMA; Sigma Aldrich, St Louis, MO, USA),
500 ng/ml ionomycin (Sigma Aldrich), and 3 μg/ml
brefeldin A (eBioscience, San Diego, CA, USA).
Fixation and permeabilisation were performed using the
Intracellular Fixation and Permeabilization Buffer set
(eBioscience), followed by staining for intracellular cyto-
kines (ESM Table 1) for 30 min. The samples were
acquired on FACSCanto II (BD Biosciences, San Jose,
CA , USA) o r Cy to f l e x S (Beckman Cou l t e r ,
Indianapolis, IN, USA) flow cytometers (ESM Table 1).
Coded samples were used throughout, and flow-
cytometric data was analysed by FlowJo v10.4.2 (BD)
blinded to the clinical classification of the sample.
Statistical analyses Statistical analyses were performed
using Prism software version 7.05 (GraphPad Software,
San Diego, CA, USA). Mann–Whitney U test or
Kruskal–Wallis test with Dunn’s multiple comparison post
hoc test were used for statistical comparisons. No power
calculations were made as the study was exploratory in
nature with very limited previous data to support the calcu-
lations, and sample sizes were determined in part by feasi-
bility. Age as a covariate was addressed by comparing the
slopes and/or elevations of linear regression lines.
Relationships between different variables were examined
using Spearman correlation coefficient. To increase statis-
tical power, samples from different study groups were
pooled for correlation analyses in cases where the slopes
of the linear regression lines did not differ statistically
between the study groups. A p value <0.05 was considered
to indicate statistical significance.
Results
Decreased frequency of MAIT cells in AAb+ children who later
progressed to type 1 diabetes and in adult patients a short
time after onset of diabetes We first analysed the frequency
of circulating CD3+Vα7.2+CD161+ MAIT cells (Fig. 1a and
ESM Fig. 1) in paediatric and adult cross-sectional cohorts
(Table 1). In the paediatric cohort, the frequency of MAIT
cells within the CD3+αβ+ T cell compartment was similar
across the study groups (Fig. 1b). In accordance with previous
reports [18, 21, 22], the frequency of MAIT cells demonstrat-
ed considerable interindividual variation and a strong positive
correlation with the age of children (r = 0.59, p < 0.0001),
with almost a tenfold increase in mean frequency between
the ages of 2 and 15 years (Fig. 1c). However, even after
stratification by age, we observed no differences in total
MAIT cell frequencies between the study groups (Fig. 1c).
Moreover, sex, HLA class II genotype, and blood glucose
and HbA1c levels did not appear to affect MAIT cell frequen-
cies in the paediatric cohort (ESM Fig. 2). Although the
frequency of MAIT cells was overall unaltered in AAb+ at-
risk children (Fig. 1b), we interestingly observed that those
AAb+ children who later progressed to type 1 diabetes had a
decreased frequency of MAIT cells compared with control
individuals (median 0.44% vs 0.96% of CD3+ T cells, p =
0.04; Fig. 1d). This result remained significant even after strat-
ifying for age (Fig. 1e).
In the adult cohort, no differences in the frequency of
MAIT cells were observed between adult patients with type
1 diabetes and healthy control individuals (Fig. 1f). Moreover,
the frequency of MAIT cells in adults did not demonstrate
correlation with age, sex, BMI or HbA1c levels, or the duration
of disease (ESM Fig. 2). However, we noted that some adult
patients with a short disease duration had extremely low
MAIT cell frequencies for adult individuals (<0.6% of CD3+
T cells; ESM Fig. 2). Consequently, when adult patients with
diabetes were arbitrarily divided into two groups based on
disease duration [<6 (mean 2.6) and >6 (mean 15.5) years
after diagnosis], five of the ten patients with <6 years after
Table 1 Characteristics of study
participants Participant group n (male/female) Age (years)
(mean ± SD)
Range (years) T1D duration
(mean ± SD)
Range
Paediatric T1D 51 (25/26) 8.6 ± 3.9 2–15 <1 week N/A
Paediatric AAb+ 27 (14/13) 8.6 ± 4.5 2–15 N/A N/A
Progressors 11 (6/5) 7.7 ± 4.5 2–13 N/A N/A
Nonprogressors 16 (8/8) 9.0 ± 4.5 2–15 N/A N/A
Paediatric control 113 (64/49) 8.9 ± 3.9 2–15 N/A N/A
Adult T1D 33 (19/14) 27.1 ± 6.4 19–39 11.9 ± 8.0 y 0.4–30 y
Adult control 37 (14/23) 26.2 ± 4.4 20–38 N/A N/A
N/A, not applicable; T1D, type 1 diabetes; y, years
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diagnosis had a markedly lower frequency of MAIT cells
compared with the 23 patients with >6 years after diagnosis
or the 37 healthy control individuals (Fig. 1g). The median
frequency of MAIT cells in patients with <6 years after diag-
nosis was 0.87% compared with 2.19% in healthy control
individuals (p = 0.007; Fig. 1g).
In conclusion, no drastic changes in peripheral blood
MAIT cell frequencies were observed in individuals with type
1 diabetes-associated autoimmunity. However, in subgroup
analyses AAb+ at-risk childrenwho later progressed to clinical
diabetes as well as adult patients a short time after diagnosis
displayed lower frequencies of circulating MAIT cells.
Increased proportion of CD8−CD27− MAIT cells in children
with newly diagnosed type 1 diabetes We next analysed the
frequencies of MAIT cell subsets expressing CD8 and/or
CD27 (Fig. 2a). In the paediatric cohort, the proportion of
CD8+CD27+ MAIT cells was decreased and that of
CD8−CD27− MAIT cells increased in children with type 1
diabetes compared with control children (median 63.9% vs
67.1% of MAIT cells, p = 0.04, and median 4.6% vs 3.1%
of MAIT cells, p = 0.004, respectively; Fig. 2b, c), while the
CD8+CD27− and CD8−CD27+ MAIT cell subsets remained
unaltered (ESM Fig. 3). These results remained significant
even after stratifying for age (Fig. 2d, e). Importantly, no
Fig. 1 Decreased frequency of circulating MAIT cells in AAb+ children
who progressed to type 1 diabetes (T1D) and in adult patients with a short
duration of T1D. Representative example of flow cytometry gating of
CD3+Vα7.2+CD161+ MAIT cells (a). The frequency of circulating
MAIT cells in control, AAb+ and T1D groups in the paediatric cohort
(b). Linear regression lines for log10-transformed MAIT cell frequencies
vs age were calculated for the control, AAb+ and T1D groups (c). The
slopes and elevations of the regression lines were not statistically different
between the groups. Correlation with age was calculated by pooling all
samples analysed and is expressed together with the p value on the plot.
MAIT cell frequency in AAb+ children who did not progress (NP) or
progressed (P) to T1D during the follow-up (d). Linear regression lines
for log10-transformed MAIT cell frequencies vs age were calculated for
the control, AAb+ non-progressor and AAb+ progressor groups (e). The
elevations of the regression lines were statistically different among the
groups (p < 0.05). Frequency of MAIT cells in adult healthy control
individuals and adult patients with T1D (f) and in adult T1D patients with
<6 years or >6 years since T1D diagnosis (g). (b, d, f, g) Median values
with IQRs are shown, plotted on a log10 scale. *p < 0.05, **p < 0.01;
Kruskal–Wallis test with Dunn’s post hoc test
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differences in conventional CD3+Vα7.2+CD161− (non-
MAIT), CD8+CD27+ or CD8−CD27− T cell frequencies were
observed between the groups (ESM Fig. 3), demonstrating
that the observed alterations are specific to MAIT cells. No
differences in the frequencies of CD8+CD27+ or CD8−CD27−
MAIT cells were observed in AAb+ children, even after strat-
ification for progressors and nonprogressors, or in adult
patients with type 1 diabetes (Fig. 2b, c and ESM Figs 3 and
4). There were also no differences in MAIT cells expressing
the activation markers PD-1 and CD25 between the study
groups in either the paediatric or adult cohorts (Fig. 2f, g
and ESM Figs 3 and 4). In conclusion, we observed an
increased proportion of CD8−CD27− MAIT cells in children
with newly diagnosed type 1 diabetes.
Decreased CCR5, β7 integrin and IFN-γ expression on MAIT
cells in children with newly diagnosed type 1 diabetes To
better characterise the phenotype of MAIT cells during the
progression to type 1 diabetes, we analysed the expression
of homing receptors and cytokine production by MAIT cells
in the paediatric cohort (ESM Fig. 1). MAIT cells express
higher levels of CCR5 andCCR6 but similar levels ofβ7 integrin
compared with non-MAIT T cells (Fig. 3a–c). We observed
decreased levels of CCR5 and β7 integrin but not CCR6 expres-
sion on MAIT cells in children with type 1 diabetes compared
with control children (median 90.0% vs 94.3% CCR5+ MAIT
cells, p = 0.02, and median 73.5% vs 81.7% of β7 integrin+
MAIT cells, p= 0.004, respectively; Fig. 3d–f), even after strati-
fication by age (ESM Fig. 5). The decrease in CCR5 expres-
sion appeared to be specific to MAIT cells since it was
not altered in non-MAIT T cells (ESM Fig. 5). In contrast,
β7 integrin expression was also decreased in non-MAIT T
cells (as well as total CD3+ T cells) in children with type
1 diabetes compared with control children (median 66.8%
vs 77.5% of non-MAIT T cells, p < 0.0001), suggesting a
more global alteration of β7 integrin expression on T cells
in children with type 1 diabetes (Fig. 3g and ESM Fig. 5).
No changes in CCR5, CCR6 or β7 integrin expression
were observed in AAb+ children (Fig. 3d–f and ESM
Fig. 4).
Fig. 2 Proportional increase of
CD8−CD27− MAIT cells in
children with newly diagnosed
type 1 diabetes (T1D).
Representative example of flow
cytometry gating of CD8 and
CD27 expression on MAIT cells
(a). Proportions of CD8+CD27+
(b) and CD8−CD27− (c) MAIT
cells in control, AAb+ and T1D
groups. Linear regression lines for
CD8+CD27+ (d) and
CD8−CD27− (e) MAIT cell
frequencies vs age were
calculated for the control, AAb+
and T1D groups. The elevations
of the regression lines were
significantly different among the
groups (p < 0.05). Correlation
with age was calculated by
pooling all samples analysed and
is expressed together with
p values on the individual plots.
Proportions of PD-1+ (f) and
CD25+ (g) MAIT cells in control,
AAb+ and T1D groups. (b, c, f, g)
Median values with IQRs are
shown. *p < 0.05, **p < 0.01;
Kruskal–Wallis test with Dunn’s
post hoc test
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To investigate the cytokine production profile of circulating
MAIT cells, we stimulated PBMCs with PMA and ionomycin
and analysed the production of IFN-γ, IL-17A and IL-4 (Fig.
3h, i). The frequency of IFN-γ+ MAIT cells was reduced in
children with type 1 diabetes compared with control children
(median 57.1% vs 69.3% of MAIT cells, p = 0.04; Fig. 3j).
However, no differences in the frequencies of IL-17A+, IL-4+,
IFN-γ+IL-17A+ or IFN-γ+IL-4+ MAIT cells were observed
(Fig. 3k, l and ESM Fig. 5). The frequency of IFN-γ+ non-
MAIT T cells was not altered (ESM Fig. 5). Once again, no
differences in cytokine production were observed in AAb+ chil-
dren (Fig. 3j–l and ESM Fig. 4). In conclusion, we observed that
the expression of CCR5 and β7 integrin and the production of
IFN-γ by MAIT cells were lower in children with newly diag-
nosed type 1 diabetes.
Lower expression of β7 integrin and lower production of IFN-γ
by CD8−CD27− MAIT cells We next analysed whether the
observed decrease in CCR5, β7 integrin and IFN-γ expres-
sion was mechanistically linked to the proportional
Fig. 3 Lower expression of
CCR5, β7 integrin and IFN-γ on
MAIT cells from children with
newly diagnosed type 1 diabetes
(T1D). Representative examples
of CCR5 (a), CCR6 (b) and β7
integrin (c) staining in
fluorescence minus one (FMO)
control (dotted lines), non-MAIT
T cells (dashed lines) and MAIT
cells (solid lines). Frequencies of
CCR5+ (d), CCR6+ (e) and β7
integrin+ (f) MAIT cells as well as
β7 integrin+ non-MAIT T cells
(g) in control, AAb+ and T1D
groups. Representative examples
of IFN-γ, IL-17A and IL-4
production by MAIT cells (h, i).
Frequencies of IFN-γ+ (j), IL-
17A+ (k) and IL-4+ (l) MAIT cells
in control, AAb+ and T1D groups.
(d–g, j–l) Median values with
IQRs are shown. *p < 0.05, **p <
0.01, ***p < 0.001; Kruskal–
Wallis test with Dunn’s post hoc
test
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increase in CD8−CD27− MAIT cells in children with
type 1 diabetes. The frequencies of β7 integrin+ and
IFN-γ+ MAIT cells inversely correlated with the
frequencies of CD8−CD27− MAIT cells in the paediatric
cohort, while the frequencies of CCR5+ MAIT cells did
not demonstrate such correlation (Fig. 4a–c).
To study this further, we analysed additional paediatric
healthy donors with a broader flow cytometry panel incorpo-
rating all the markers in the same analysis. In line with previ-
ous studies [21, 40, 41], we observed that around 80–90% of
MAIT cells are CD8+ and almost all the remaining cells are
double negative (DN), while CD4+ and double positive (DP)
MAIT cells are extremely rare (Fig. 4d, e). Therefore, the
CD8−CD27− MAIT cells analysed so far are most likely to
represent DNCD27− cells. CD8+CD27+MAIT cells represent
about 80% of circulatingMAIT cells followed byminor popu-
lations of DN CD27+, CD8+CD27− and DN CD27− MAIT
cells (Fig. 4f). Next, we examined whether the expression of
homing receptors and/or cytokines differs between the CD27-
positive or -negative CD8+ and DN subsets. The expression of
CCR5 was lower on DN CD27− and DN CD27+ compared
with CD8+CD27+ MAIT cells (Fig. 4g). Moreover, the
frequencies of β7 integrin+ and IFN-γ+ MAIT cells were
lower in CD8+CD27− and DN CD27− MAIT subsets
compared with CD8+CD27+ MAIT cells (Fig. 4h, i). Of note,
the frequencies of IL-4+ MAIT cells were also lower but those
of IL-17A+ MAIT cells higher in CD8+CD27− and DN
CD27− MAIT subsets compared with CD8+CD27+ MAIT
cells (ESM Fig. 5).
Collectively, these analyses infer that the observed increase in
CD8−CD27−MAIT cells in childrenwith type 1 diabetes (Fig. 2c)
probably results from a proportional shift towards an increased
frequency of DN CD27− MAIT cells. This, in turn, explains the
decreasedβ7 integrin expression and IFN-γ production byMAIT
cells from children with type 1 diabetes (Fig. 3), as they demon-
strate an inverse correlation with the frequency of CD8−CD27−
MAIT cells and their expression ismarkedly lower onDNCD27−
MAIT cells compared with CD8+CD27+ MAIT cells.
Fig. 4 CCR5, β7 integrin and
IFN-γ expression on
CD8−CD27− MAIT cells. Linear
regression lines for CCR5+ (a),
β7 integrin+ (b) and IFN-γ+ (c)
MAIT cell frequencies vs
CD8−CD27− MAIT cell
frequencies were calculated for
the control, AAb+ and type 1
diabetes (T1D) groups. The
slopes of the regression lines were
not significantly different
between the groups. Correlation
with CD8−CD27− MAIT cell
frequencies was calculated by
pooling all samples analysed and
is expressed together with
p values on the individual plots.
Representative example of CD8
and CD4 expression on peripheral
blood MAIT cells (d). The
frequencies of MAIT cells that
belong to the CD8+, DN, CD4+
and DP subsets (e), and that
belong to the CD8+CD27+,
CD8+CD27−, DNCD27+ and DN
CD27− subsets (f). Frequencies of
CCR5+ (g), β7 integrin+ (h) and
IFN-γ+ (i) cells within the MAIT
cell subsets. The data in (e–i)
represent a combined analysis of a
total of 17 different healthy
children. (e–i) Median values
with IQRs are shown. *p < 0.05,
**p < 0.01, ***p < 0.001;
Kruskal–Wallis test with Dunn’s
post hoc test
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Fig. 6 Increased frequency of IL-
17A-producing γδ T cells in
children with newly diagnosed
type 1 diabetes (T1D).
Frequencies of γδ T cells (a),
iNKT cells (b) and NK cells (c) in
control, AAb+ and T1D groups.
Linear regression lines for log10-
transformed γδ T cell (d), iNKT
cell (e) and NK cell (f)
frequencies vs log10-transformed
MAIT cell frequencies were
calculated for the control, AAb+
and T1D groups. The slopes and
elevations of the regression lines
were not statistically different
between the groups. Correlation
was calculated by pooling all
samples analysed and is
expressed together with p values
on the individual plots.
Frequencies of IL-17A-producing
γδ T cells (g) and iNKT cells (h)
in control, AAb+ and T1D groups.
Median values with IQRs are
shown; plotted on a log10 scale in
(b).**p < 0.01; Kruskal–Wallis
test with Dunn’s post hoc test
Fig. 5 Comparable frequencies of
CD25+CD69+ MAIT cells after
stimulation in vitro with E.coli or
the combination of IL-12 and IL-
18 in children with type 1 diabetes
(T1D), AAb+ children and control
children. Representative example
of CD25+CD69+ MAIT cells in
an unstimulated PBMC sample
(a, left), and samples stimulated at
a PBMC to E.coli ratio 1:10 (a,
middle) or with IL-12+IL-18 (a,
right). Frequencies of
CD25+CD69+ MAIT cells in
samples stimulated at a PBMC to
E.coli ratio 1:1 (b) and 1:10 (c), or
with IL-12 and IL-18 (d) from
paediatric control, AAb+ and T1D
individuals. (b–d) Median values
with IQRs are shown
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MR1-dependent and cytokine-driven functional responses
are not altered in MAIT cells from children with newly diag-
nosed type 1 diabetes or from AAb+ at-risk children To further
investigate MAIT cell functionality during the progression of
type 1 diabetes, PBMCs from 12 children with type 1 diabetes,
nine AAb+ children and 18 control children were stimulated
either with whole E.coli bacteria (MR1-dependent activation
[39]) or with the combination of IL-12 and IL-18 (MR1-inde-
pendent activation [42]). Activation of MAIT cells (CD69 and
CD25 upregulation) was subsequently analysed (Fig. 5a). No
differences in the frequencies of CD25+CD69+MAIT cells were
observed between the study groups upon stimulation with E.coli
at two different concentrations (Fig. 5b, c) or with IL-12 and IL-
18 (Fig. 5d). Moreover, no differences in the frequencies of
CD25+CD69+ non-MAIT T cells were observed between the
study groups (ESM Fig. 6). When anti-MR1 blocking antibodies
were added to the E.coli stimulation, the frequencies of
CD25+CD69+ MAIT cells but not non-MAIT cells were mark-
edly reduced (ESM Fig. 6), confirming that E.coli activates
MAIT cells throughMR1 presentation. In conclusion, no impair-
ment of MAIT cell activation was observed in children with type
1 diabetes or AAb+ at-risk children.
Increased frequency of IL-17A-producing γδ T cells in children
with newly diagnosed type 1 diabetes Finally, we analysed
other peripheral blood UCT subsets, namely γδ T cells and
iNKT cells, as well as natural killer (NK) cells in our paediat-
ric cohort (ESM Figs 1 and 7). The frequencies of these cell
types were similar between the study groups (Fig. 6a–c and
ESM Fig. 4). Interestingly, the frequencies of γδ T cells,
iNKT cells and NK cells appeared to correlate with circulating
MAIT frequencies (Fig. 6d–f). However, in contrast to MAIT
cells, the frequencies of γδ T cells or iNKT cells did not
increase with age and NK cells displayed only a modest posi-
tive correlation with age (ESM Fig. 8).
To investigate whether there are phenotypic alterations in
γδ T cells and iNKT cells, we analysed the production of
IFN-γ, IL-17A and IL-4. No differences in the frequencies
of IFN-γ+ and IL-4+ γδ T cells and iNKT cells were observed
between the study groups (ESM Fig. 8). However, IL-17A+
γδ T cells but not iNKT cells were more abundant in children
with newly diagnosed type 1 diabetes compared with control
children (median 1.58% vs 1.09% of γδ T cells, p = 0.002;
Fig. 6g and h and ESM Fig. 8). In conclusion, no changes in
γδ T cells, iNKT cells and NK cells were observed in children
with newly diagnosed type 1 diabetes, with the exception of
an increased production of IL-17A by γδ T cells.
Discussion
We observed multiple subtle alterations in the peripheral
MAIT cell compartment through the analysis of cross-
sectional cohorts of individuals at different stages of type 1
diabetes progression (Fig. 7). In children with newly diag-
nosed type 1 diabetes, the proportion of CD8−CD27− (DN)
MAIT cells was increased and the expression of the homing
receptors CCR5 and β7 integrin, as well as the production of
IFN-γ by MAIT cells was decreased. Moreover, the frequen-
cy of MAIT cells was decreased in AAb+ at-risk children who
later progressed to type 1 diabetes and in adult patients with a
short duration of type 1 diabetes. No alterations in MAIT cells
were observed in AAb+ at-risk children who did not progress
to diabetes during our follow-up or in adult type 1 diabetes
patients with a long disease duration. These alterations were
independent of age, which is a major factor affecting periph-
eral blood MAIT cell frequencies in children (Fig. 1c and [18,
21, 22]). Moreover, sex, HLA class II genotype, BMI or level
of dysglycaemia were not observed to affect MAIT cell
f requencies in our study cohor ts (ESM Fig. 2) .
Consequently, our results suggest a temporal association
between circulating MAIT cell alterations and the clinical
onset of type 1 diabetes.
AAb+ (NP) AAb+ (P) T1D (ND) T1D (E) T1D (E, <6y) T1D (E, >6y)
MAIT ↔ MAIT ↓ MAIT ↔
CD8−CD27− MAIT ↑
CCR5+ MAIT ↓
β7 integrin+ MAIT ↓
IFN-γ+ MAIT ↓
MAIT ↓ MAIT ↔
MAIT ↓ [36] MAIT ↔ [36] MAIT ↓ [35]
CCR6+ MAIT ↓ [35]
CD25+ MAIT ↑ [35]
PD-1+ MAIT ↑ [35]
IFN-γ+ MAIT ↓ [35]
‘MAIT-like’ ↔ [34]
MAIT ↔ [35]
CD27− ‘MAIT-like’ ↑ [34]
IFN-γ+ MAIT ↓ [35]
a b
Fig. 7 Peripheral blood MAIT cell alterations during the progression of
type 1 diabetes (T1D). Alterations observed in our study in the paediatric
cohort (a) and adult cohort (b) are displayed above the black line and
those reported in previous studies [34–36] are listed below the black line.
E, established (more than 10 days after diagnosis); ND, newly diagnosed
(less than 10 days after diagnosis); NP, non-progressor; P, progressor
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Of the MAIT cell alterations observed here, decreased
expression of CD27 and production of IFN-γ have also been
reported by others in patients with type 1 diabetes [34, 35]
(Fig. 7). Some discrepancies between our and previous studies
also remain (Fig. 7). Rouxel et al [35] reported a decreased
frequency of total blood MAIT cells in children with type 1
diabetes, whereas this was not observed in our study. Also, the
study by Harms et al did not detect differences in the frequen-
cy of ‘MAIT-like’ cells in children with type 1 diabetes [34].
A more recent study by the same group reported a decreased
MAIT cell frequency in AAb+ at-risk individuals, especially
in those who did not progress to type 1 diabetes [36], which
contrasts with our finding of a decreased frequency of MAIT
cells in AAb+ at-risk children who progressed to type 1 diabe-
tes. Differences in gating strategy for MAIT cells [34], as well as
how stringently the study cohorts have been matched for age and
HLA background, may explain some of these discrepancies.
Moreover, it is important to note that several additional factors
that are difficult to control for, including previous infection histo-
ry, the use of corticosteroids and antibiotics, as well as the pres-
ence of other inflammatory or metabolic diseases, can affect the
circulatingMAIT cell compartment considerably [43]. Due to the
considerable interindividual variation in peripheral blood MAIT
cell frequencies (Fig. 1c), subtle alterations may also be difficult
to reproducibly detect with the cohort sizes analysed in studies
performed thus far.
A clear (two- to fivefold) decrease in peripheral blood
MAIT cell frequencies has consistently been observed in both
patients with IBD [23–26] and SLE [27, 28]. In contrast, not
all studies report decreased blood MAIT frequencies in
patients with multiple sclerosis [31, 44] and rheumatoid arthri-
tis [30], a finding that parallels the observationsmade in type 1
diabetes. Therefore, it is possible that alterations in blood
MAIT cells may be less prominent in organ-specific autoim-
mune diseases (type 1 diabetes, multiple sclerosis and rheu-
matoid arthritis) compared with autoimmune diseases associ-
ated with a more systemic inflammatory response (IBD and
SLE). In other autoimmune diseases, the decrease of blood
MAIT cells has been attributed to either a preferential homing
of the cells to inflamed target tissues [23, 25–27, 29, 33] or
increased apoptosis caused by the inflammatory milieu [24,
28], which both may be less prominent in type 1 diabetes.
We provide evidence that all the observed alterations in
MAIT cells in children with type 1 diabetes are likely mech-
anistically linked together. Compared with the most abundant
CD8+CD27+MAIT subpopulation, CD8−CD27− (DN)MAIT
cells express less CCR5 and β7 integrin and produce less
IFN-γ (Fig. 4). Therefore, the proportional increase of
CD8−CD27− MAIT cells likely directly explains the reduced
CCR5 and β7 integrin expression and IFN-γ production by
circulating MAIT cells from children with type 1 diabetes.
Alternatively, the decrease in the expression of the homing
receptors CCR5 andβ7 integrin could also be due to increased
trafficking to inflamed tissues in children with type 1 diabetes,
which would cause a proportional decrease in MAIT cells
expressing these markers in the circulation. Interestingly, a
proportional increase of blood (CD8−) DN MAIT cells has
also been reported in patients with multiple sclerosis [31].
Recent research suggests that DN MAIT cells are a function-
ally mature effector subpopulation of MAIT cells that, at least
in vitro, appear to derive from CD8+ MAIT cells under chron-
ic TCR stimulation [45]. Less is known about the relevance of
CD27 on MAIT cell functionality. However, at least in
conventional T cells the loss of CD27 is associated with a
more terminal effector phenotype of T cells [46].
Collectively, our results therefore suggest a shift towards a
more terminally differentiated MAIT phenotype in blood at
the time of type 1 diabetes diagnosis.
One caveat of our study is that we could only analyse cross-
sectional cohorts and further work on longitudinal sample sets
would be required to confirm the temporal association of periph-
eral blood MAIT cell alterations and the onset of type 1 diabetes.
Another obvious caveat of our study is that we could only analyse
MAIT cells in blood samples, where immune changes are likely
to be minor compared with those in inflamed islets. In the NOD
mouse model, MAIT cells accumulate in pancreatic islets during
disease progression and increase their expression of IFN-γ and
granzymeB [35]. However, in the absence ofMAIT cells, there is
an accelerated progression to diabetes in NOD mice, suggesting
that MAIT cells may actually have a protective role in type 1
diabetes, possibly due to their role in supporting gut integrity
[35]. Importantly, a recent study showed that MAIT cells were
completely absent in human insulitic lesions in pancreas biopsies
obtained from six patients with newly diagnosed type 1 diabetes
[47]. Collectively, these studies support the notion that MAIT
cells may not play a direct role in the beta cell destructive process
in human type 1 diabetes, but that their peripheral blood alter-
ations rather reflect a response to the inflammatory changes
during diabetes progression.
The frequencies of other circulatingUCT subtypes, namelyγδ
T cells and iNKT cells, were not altered either in children with
newly diagnosed type 1 diabetes or AAb+ at-risk children.
However, in line with previous reports [21, 22, 32], the frequen-
cies of these cell subtypes correlated with MAIT cell frequencies
in blood, suggesting that MAIT cells, γδ T cells and iNKT cells
may share common developmental and/or homeostatic factors. In
contrast to earlier reports [48, 49], we did not observe a reduced
frequency of NK cells in children with type 1 diabetes. No chang-
es in the cytokine production patterns of γδ T cells and iNKT
cells were observed, except for an increased frequency of IL-
17A+ γδ T cells in children with type 1 diabetes. Interestingly,
IL-17A+ γδ T cells have been demonstrated to be an important
pathogenic effector cell subset in the NOD mouse model [50].
Therefore, our current observation may warrant further investiga-
tion on the role of IL-17A-producing γδ T cells in human type 1
diabetes. Of note, in addition to MAIT cells we also observed
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decreased expression ofβ7 integrin on conventional CD3+T cells
in children with type 1 diabetes (Fig. 3), which to our knowledge
has not been reported previously. This finding would suggest a
more global defect inmucosal T cell homing in childrenwith type
1 diabetes, which should also be explored in more detail in the
future.
In conclusion, we present here a thorough analysis of
peripheral blood MAIT cells during human type 1 diabetes
development, utilising the largest and most stringently age-
matched cohorts analysed so far, to our knowledge. We were
able to demonstrate subtle alterations in circulating MAIT
cells, suggesting a shift towards a more terminally differenti-
ated MAIT phenotype in children with newly diagnosed type
1 diabetes. We also observed a decreased frequency of MAIT
cells in AAb+ children who later progressed to type 1 diabetes
as well as in adult type 1 diabetes patients with a short disease
duration. Taken together, our current data suggest that periph-
eral blood MAIT cell alterations are temporally associated
with the clinical onset of type 1 diabetes.
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